Rachel Klemovitch, Assistant Editor02.15.24
The American Academy of Orthopeadic Surgeons (AAOS) has named CytexOrtho the winner of the OrthoPitch Technology Competition at the AAOS 2024 Annual Meeting in San Francisco.
CytexOrtho is a pre-clinical medical device company focusing on orthopaedic treatment options for cartilage repair. The company presented its ReNew Hip implant, designed to naturally restore joints instead of artificially replacing them. The ReNew Hip implant is a solution for those who have early hip disease and are too young for a total hip replacement.
"The ReNew Hip implant is comprised of two very special components – one is a 3D-woven textile, and the other is a high-precision, Tru3D printed component," said founded and CEO of CytexOrtho, Bradley Estes, during the live pitch event. "The integration of these two components gives us an implant that not only recreates the form and contour of a healthy articular joint surface but also recreates the function of articular cartilage and bone."
The ReNew Hip technology has received its FDA Breakthrough Device designation and is set to finish phase 1 clinical trials and launch phase 2 once the company receives additional funding.
With this new technology, surgeons remove only the damaged tissue and replace it with the implant. As the implant restores join contour and function, over time the cells can move into the gaps and layers of the implant to form functional tissue while the implant is absorbed into the body.
"Being named winner of the first OrthoPitch competition validates the hard work our team at CytexOrtho has devoted to helping patients through this technology," Dr. Estes said. "As we approach first-in-human clinical trials this year, we're thrilled to receive this recognition from AAOS and are looking forward to promising outcomes."
As the grand prize winner CytexOrtho receives:
Winners are decided based on a multi-staged review process conducted by the AAOS Devices, Biologics, and Technology (DBT) Committee. The committee looks at ease to market, reimbursement coverage, commercialization, and impact on market. At the AAOS Annual Meeting the top four submission pitch their concepts live, after which a winner is decided.
The top four submissions included CytexOrtho, Biomedical Bonding AB, Solenic Medical, and nView Medical.
"Orthopaedic surgeons are at the forefront of new procedures and technologies to optimize patient care in an evidence-based approach," said Jason L. Dragoo, MD, FAAOS, and DBT Committee chair. "With programs such as OrthoPitch, we're able to nurture innovation(s) from the ground up and witness energy and excitement for the future of musculoskeletal care. The experience of being in person at the AAOS Annual Meeting gave new meaning to 'pitching a deal' and allowed each finalist the opportunity to receive valuable feedback."
CytexOrtho is a pre-clinical medical device company focusing on orthopaedic treatment options for cartilage repair. The company presented its ReNew Hip implant, designed to naturally restore joints instead of artificially replacing them. The ReNew Hip implant is a solution for those who have early hip disease and are too young for a total hip replacement.
"The ReNew Hip implant is comprised of two very special components – one is a 3D-woven textile, and the other is a high-precision, Tru3D printed component," said founded and CEO of CytexOrtho, Bradley Estes, during the live pitch event. "The integration of these two components gives us an implant that not only recreates the form and contour of a healthy articular joint surface but also recreates the function of articular cartilage and bone."
The ReNew Hip technology has received its FDA Breakthrough Device designation and is set to finish phase 1 clinical trials and launch phase 2 once the company receives additional funding.
With this new technology, surgeons remove only the damaged tissue and replace it with the implant. As the implant restores join contour and function, over time the cells can move into the gaps and layers of the implant to form functional tissue while the implant is absorbed into the body.
"Being named winner of the first OrthoPitch competition validates the hard work our team at CytexOrtho has devoted to helping patients through this technology," Dr. Estes said. "As we approach first-in-human clinical trials this year, we're thrilled to receive this recognition from AAOS and are looking forward to promising outcomes."
As the grand prize winner CytexOrtho receives:
- Exposure to top seed and early-stage investors, strategists and industry members
- One-on-one coordinated meetings with nine or more leading MedTech investors
- One set access to Axion Health’s Market Intelligence Platform
- Regulatory or reimbursement assessment by a MCRA consultant
- A complementary booth at AAOS 2025 Annual Meeting in San Diego
- A 20-minute time slot at the Innovation Theater at AAOS 2024 and 2025 Annual Meetings
- One complimentary webinar with AAOS
Winners are decided based on a multi-staged review process conducted by the AAOS Devices, Biologics, and Technology (DBT) Committee. The committee looks at ease to market, reimbursement coverage, commercialization, and impact on market. At the AAOS Annual Meeting the top four submission pitch their concepts live, after which a winner is decided.
The top four submissions included CytexOrtho, Biomedical Bonding AB, Solenic Medical, and nView Medical.
"Orthopaedic surgeons are at the forefront of new procedures and technologies to optimize patient care in an evidence-based approach," said Jason L. Dragoo, MD, FAAOS, and DBT Committee chair. "With programs such as OrthoPitch, we're able to nurture innovation(s) from the ground up and witness energy and excitement for the future of musculoskeletal care. The experience of being in person at the AAOS Annual Meeting gave new meaning to 'pitching a deal' and allowed each finalist the opportunity to receive valuable feedback."